UK biotech Orchard Therapeutics opens US operations in California
Posted: 6 October 2016 | Niamh Louise Marriott, Digital Content Producer | No comments yet
Foster City will serve as headquarters for Orchard Therapeutics North America, and will provide the central base for laboratory operations associated…
Orchard Therapeutics, a UK-based biotechnology company, opens its US operations in Foster City, California. Orchard is developing a global platform of ex-vivo autologous gene therapies in serious and life-threatening orphan diseases.
In the US, Orchard has collaborations with the University of California Los Angeles and Boston Children’s Hospital, and with leading manufacturing partners specialised in gene and cell therapy.
Lab operations
Foster City will serve as headquarters for the Company’s North American subsidiary, Orchard Therapeutics North America, and will provide the central technical base for laboratory operations associated with the development and validation of manufacturing processes and analytical methods for the company’s products.
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
Dr Stewart Craig, Orchard’s CMO, commented, “We are building a world-class team of experts in the development, manufacture, testing and delivery of cell-based gene therapy products. This facility represents a next key step in establishing a central technical capability to support the global clinical development and commercialisation of Orchard’s products”.
Immunodeficiency
Orchard’s lead program in severe combined immunodeficiency due to adenosine deaminase deficiency is an advanced clinical development, with a total of 39 patients treated as of September 2016.
Dr Alexander Pasteur, interim CEO, added, “Our goal is to become a category leader in ex-vivo autologous gene therapy for rare conditions. The opening of our US operations in California is a key step in building the global platform that can deliver Orchard’s transformative therapies to patients wherever they are.”
Related topics
Ex Vivo, Gene Therapy
Related organisations
Orchard Therapeutics
